NOK 2.44
(-0.61%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 58.91 Million NOK | 28.62% |
2022 | 45.8 Million NOK | -70.67% |
2021 | 156.15 Million NOK | 14.87% |
2020 | 135.94 Million NOK | 2874.01% |
2019 | 4.57 Million NOK | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q2 | 60.1 Thousand NOK | 0.0% |
2024 Q1 | 60.1 Thousand NOK | -99.9% |
2023 FY | 58.91 Million NOK | 28.62% |
2023 Q4 | 58.91 Million NOK | 0.0% |
2023 Q2 | 20.7 Million NOK | 32523.8% |
2023 Q1 | -63.84 Thousand NOK | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Arctic Bioscience AS | 41.69 Million NOK | -41.29% |
Aqua Bio Technology ASA | 15.72 Million NOK | -274.672% |
ArcticZymes Technologies ASA | 30.02 Million NOK | -96.197% |
BerGenBio ASA | 46.85 Million NOK | -25.718% |
Hofseth BioCare ASA | 348.97 Million NOK | 83.119% |
PCI Biotech Holding ASA | 5 Million NOK | -1076.318% |
Ultimovacs ASA | 69.64 Million NOK | 15.418% |